Navigation Links
Vaginal Gel That Protects Against HIV To Hit The Markets By 2010

According to the researchers, a vaginal gel, which is said to be much safer and more effective in protecting women against HIV, the virus that causes AIDS// expected to hit the markets by 2010.

Currently, microbe-killing vaginal gels are being tested in a number of clinical trials involving thousands of women. Results should be available within two years, the Associated Press reported.

According to foodconsumer.org, if the trials prove the gels are effective and if governments fast-track their approval, they could be on the market as early as 2010, Gita Ramjee, director of the HIV prevention research unit at South Africa's Medical Research Council, said at a news conference in Cape Town before an international conference on microbicides.

More than 1,000 scientists and researchers are attending the conference, which is co-sponsored by the World Health Organization.

In many parts of the world, HIV infections are increasing more rapidly among women than men. Half of all adults with HIV are female, according to the United Nations.

A microbicide that's 60 percent effective against HIV that's used by only 20 percent of women in 73 developing countries could prevent 2.5 million HIV infections, the London School of Tropical Hygiene has calculated, the AP reported.


'"/>




Page: 1

Related medicine news :

1. Vaginal Birth After C-section Dangerous For Both Mother And Baby
2. PET Scanner detects more Vaginal cancer than CT scans
3. Vaginal Vaccine may prevent periodic infections
4. Vaginal atrophy drug Ospemifene found effective in breast cancer Prevention
5. Increased Risk Of HIV Transmission Following Vaginal Washing
6. Risk Of AIDS Rises With Vaginal Washes
7. Vaginal massage during pregnancy avoids Episiotomy procedure
8. Vaginal Delivery Should Be an Option after Multiple Cesareans
9. New Laparoscopic Surgery to Correct Vaginal Vault Prolapse Is Effectual Than the Conventional Surgery
10. Extra Vaginal Bleed After ā€˜C’ Section Can be Prevented By Contraceptive Pils
11. Risk of Hemorrhage Increased in Vaginally Born Babies
Post Your Comments:
(Date:10/3/2008)...- Inc. Magazine recently included,Connolly Consult...ing,private companies in the country. The list is ...segment of the economy -- America,s,independent-mi...ies,represent the backbone of the U.S. economy., ...03/NY36880LOGO ), Connolly Consulting,s consiste...
(Date:10/3/2008)... Discrimination; Recognizes,Importance of Mental H.../PRNewswire-USNewswire/ -- Mental Health,America t...approval of a,mental health parity legislation tha...ion against Americans with mental health and subst...lans., The legislation, which recognizes the impo...
(Date:10/3/2008)...search Foundation(R) Collection of, Bouquets to T...Research, LOS ANGELES, Oct. 3 /PRNewswire/ -- Tel...g only hand-arranged, hand-delivered floral,arrang...nth-long,collaboration with The City of Hope, John... Cancer Center in southern California and national...
(Date:10/3/2008)...- As the population ages, a big,question employers...e the,financial crunch of an illness?", In most c...eck to,paycheck and now need two incomes to provid... spouses becomes critically ill and unable to work...ut the healthy,employee/spouse is strained by the ...
Breaking Medicine News(10 mins):Health News:Connolly Consulting Makes the 2008 Inc. Magazine's List of America's 5000 Fastest Growing Companies 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 3Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 2Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 3Health News:Can Your Employees Survive the Financial Crunch of an Illness? 2
...who are overweight or obese have a greater risk of...sease, a new study by US and Australian researcher...s Jefferson University in Philadelphia and the Edi...Australia - say that being obese 'almost certainly...
...hers from Germany have discovered a novel, less in...nary veins. This technique, called ECG-gated cardi... associated with very few complications // . It is...ed diagnostic quality and treatment. A comparison...
...n cancer gel developer Peplin has said that it wou...st-action cancer cream since it was able to get an...ors for this purpose. The company based in Quee...05 compound as a treatment for actinic keratosis a...
...ube has been designed by scientists belonging to t...for delivering cells or molecules for treatment, t...ished in the Biomedical Microdevices. In the initi...ned box, but when heat is applied, the sides fold ...
Other Medicine News:Health News:Obesity could lead to Alzheimer's 2Health News:Nanocubes Designed For Delivering Cells 2
(Date:10/2/2008)... STOCKHOLM, October 2 /- Athera Biot...unced today that they have entered into a,collabor...cts for the,prevention or treatment of cardiovascu...lows the recent publication of work by Athera,scie...e of the Karolinska,Institutet. The research links...
(Date:10/2/2008)... Data Indicate Dual Modes of Action and Synergy...rstCall/ -- Access Pharmaceuticals, Inc.,(OTC Bull...eclinical,studies on Angiolix showing that by bloc...enic effect as well as a direct anti-proliferative...s of human breast cancer (MX-1),Angiolix had a si...
(Date:10/1/2008)...ta support the therapeutic potential of Amylin,s i...to obesity pharmacotherapy, SAN DIEGO, Oct. 1 /PR.... (Nasdaq: AMLN ) today announced that new data f...ed at the 2008 Annual Scientific Meeting of The,Ob...Society,s annual,meeting is one of the largest and...
(Date:10/1/2008)...Intermezzo(R) (zolpidem tartrate sublingual lozeng...ly for use in the middle of the night when ...sleep, PT. RICHMOND, Calif., Oct. 1 /PRNewswire/ ...ld specialty pharmaceutical company, announced tod...DA) to the U.S. Food and,Drug Administration (FDA)...
Breaking Medicine Technology:Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 2Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 3Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 4Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 5Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 6Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society 7Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 2Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 3Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 4Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 5Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings 6Experts discuss climate change during UH lecture series 5081 1Experts discuss climate change during UH lecture series 5081 2Telik Announces Receipt of Nasdaq Notice 7927 1Telik Announces Receipt of Nasdaq Notice 7927 2Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment 7926 1Bion Announces Approval of New Australian Patent for Low Oxygen Organic Waste Bioconversion for Livestock Waste Environmental Treatment 7926 2Army can boost mission success by better managing 5076 1Army can boost mission success by better managing 5076 2Army can boost mission success by better managing 5076 3Army can boost mission success by better managing 5076 4
...trates Continued Safety for XIENCE V with No,Late ...ac Events,Out to Three Years, BARCELONA, Spain, Ma...ta from the SPIRIT FIRST trial demonstrated no,add...o late stent,thrombosis in patients treated with e...onary Stent System or its MULTI-LINK,VISION(R) met...
...2007 /PRNewswire-FirstCall/ -- Forest,Laboratories...d,that preliminary top-line results from a 1,196 p...ebo-controlled pivotal Phase III,study demonstrate...milnacipran as a treatment of fibromyalgia syndrom...to review initial top-line,results and further ana...
Other Medicine Technology:Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 2Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 3Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 2Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 6
...) is the sulfate ester of DHEA, derived from sulfa... in adrenal and extradrenal tissues. DHEA is the m...nd is a precursor for testosterone and estrogen bi...nic activity, which for unsulfated DHEA has been e...
...ompetition principle and the microplate separation...e and a fixed amount of DHEA-S conjugated with hor... of a polyclonal DHEA-S antiserum coated onto the ...te is washed to stop the competition reaction. Hav...
Inquire
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM.
Medicine Products: